Damiano Baroncini
Overview
Explore the profile of Damiano Baroncini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
408
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iaffaldano P, Lucisano G, Guerra T, Patti F, Onofrj M, Morra V, et al.
Mult Scler
. 2022 Aug;
28(14):2243-2252.
PMID: 35971322
Background: Definitions for reliable identification of transition from relapsing-remitting multiple sclerosis (MS) to secondary progressive (SP)MS in clinical cohorts are not available. Objectives: To compare diagnostic performances of two different...
2.
Baroncini D, Ghezzi A, Guaschino C, Moiola L, Filippi M, Ianniello A, et al.
Neurol Sci
. 2022 Jul;
43(11):6415-6423.
PMID: 35781765
Background: Natalizumab (NAT) has a strong impact on disease activity of aggressive pediatric multiple sclerosis (MS), with no difference in safety profile compared to adult MS. However, available data are...
3.
Pilotto S, Gencarelli J, Bova S, Gerosa L, Baroncini D, Olivotto S, et al.
Mult Scler J Exp Transl Clin
. 2021 Dec;
7(4):20552173211059048.
PMID: 34868629
Background: The etiology of pediatric-onset multiple sclerosis is unknown although putative genetic and environmental factors appear to be involved. Among children multiple sclerosis onset occurs closer to the susceptibility window...
4.
Russo C, Sacca F, Frau J, Annovazzi P, Signoriello E, Bonavita S, et al.
Eur J Neurol
. 2021 Sep;
29(1):257-266.
PMID: 34558755
Background And Purpose: Real-world data on alemtuzumab are limited and do not provide evidence of its effectiveness after various disease-modifying therapies (DMTs). Our aim was to provide real-world data on...
5.
Baroncini D, Simone M, Iaffaldano P, Morra V, Lanzillo R, Filippi M, et al.
JAMA Neurol
. 2021 May;
78(6):726-735.
PMID: 33938921
Importance: Availability of new disease-modifying therapies (DMTs) and changes of therapeutic paradigms have led to a general improvement of multiple sclerosis (MS) prognosis in adults. It is still unclear whether...
6.
Signoriello E, Lus G, Bonavita S, Lanzillo R, Sacca F, Landi D, et al.
Mult Scler
. 2021 Apr;
28(1):93-101.
PMID: 33855897
Objectives: Switching between treatments is an opportunity for patients with multiple sclerosis (MS) to ameliorate disease control or safety. The aim of this study was to investigate the impact of...
7.
De Mercanti S, Signori A, Cordioli C, Signoriello E, Lus G, Bonavita S, et al.
J Neurol Sci
. 2021 Mar;
424:117385.
PMID: 33770708
Background: To minimize the risk of Progressive Multifocal Leukoencephalopathy and rebound in JCV-positive multiple sclerosis (MS) patients after 24 natalizumab doses, it has been proposed to extend the administrations interval....
8.
Mantero V, Baroncini D, Balgera R, Guaschino C, Basilico P, Annovazzi P, et al.
J Neurol
. 2020 Sep;
268(6):2029-2030.
PMID: 32865629
No abstract available.
9.
Signori A, Sacca F, Lanzillo R, Maniscalco G, Signoriello E, Repice A, et al.
Neurol Neuroimmunol Neuroinflamm
. 2020 Aug;
7(6).
PMID: 32801167
Objective: Cladribine tablets were tested against placebo in randomized controlled trials (RCTs). In this study, the effectiveness of cladribine vs other approved drugs in patients with relapsing-remitting MS (RRMS) was...
10.
Gastaldi M, Scaranzin S, Jarius S, Wildeman B, Zardini E, Mallucci G, et al.
J Neurol
. 2020 Jul;
267(12):3555-3564.
PMID: 32623596
Background: The detection of antibodies to myelin oligodendrocyte glycoprotein (MOG) is fundamental for the identification of MOG antibody-associated disorders (MOGAD), and the differential diagnosis of acquired demyelinating syndromes of the...